A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov
- 28 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov